Table 2 Progression-free and overall survival in recent clinical studies of nab-paclitaxel in metastatic breast cancer
From: nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings
Study, author, year | Type of study | N (ITT) | Patient population or stage of disease | Line of therapy | Regimen | PFS, months, median | OS, months, median |
|---|---|---|---|---|---|---|---|
Unselected (all subtypes; n = 5) | |||||||
 CALGB 40502, Rugo, 2015 [30] | Phase III | 799 | Stage IIIC or IV locally recurrent or MBC | First | Beva + paclitaxel 90 mg/m2 qw 3/4 | 11 | 27.4b |
Bev + nab-P 150 mg/m2 qw 3/4 | 9.3 | 23.5 | |||||
Bev + ixabepilone 16 mg/m2 qw 3/4 | 7.4 | 23.6 | |||||
 Jain, 2016 [32] | Phase II/III | 180 | MBC | Multiple (all lines) | nab-P 260 mg/m2 q3w | 7.8 | NR |
PICN 260Â mg/m2 q3w | 5.3 | NR | |||||
PICN 295Â mg/m2 q3w | 8.1 | NR | |||||
 Sun, 2014 [31] | Phase II | 73 | MBC | Multiple (all lines) | nab-P 125 mg/m2 qw 3/4 → cisplatin 75 mg/m2 q4w | 9.8 | 26.9 |
 Dent, 2013 [63] | Retrospective | 43 | MBC | Multiple (all lines) | nab-P 260 mg/m2 q3w | NR | 10.8 |
nab-P 100Â mg/m2 qw 3/4 | 13.6 | ||||||
 Aigner, 2013 [64] | Retrospective | 36 | MBC | Multiple (all lines) | nab-P 100-150 mg/m2 qw | 7.5 | 14.2 |
HER2− or TNBC (n = 4) | |||||||
 TBCRC 019, Forero-Torres, 2015 [37] | Phase II | 64 | Metastatic TNBC | Multiple (all lines) | nab-P 100 mg/m2 qw 3/4 + tigatuzumab (10 mg/kg, then 5 mg/kg q2w) | 2.8 | NR |
nab-P 100Â mg/m2 qw 3/4 | 3.7 | ||||||
 Palumbo, 2015 [38] | Phase II | 52 | HER2− MBC | Second | nab-P 260 mg/m2 q3w | 8.9 | Not yet reached |
 Hamilton, 2013 [65] | Phase II | 34 | Metastatic TNBC | First | nab-P 100 mg/m2 qw 3/4 + carbo AUC 2 qw 3/4 + bev 10 mg/kg q2w | 9.2 | NR |